Medicine and Dentistry
Prostate Cancer
100%
Osteoblast
46%
Clear Cell Renal Cell Carcinoma
36%
Bone Metastasis
36%
Androgen Receptor
30%
Endothelial Cell
26%
Metastatic Carcinoma
25%
In Vitro
25%
Cancer Cell
23%
Neoplasm
21%
Osteolysis
20%
Programmed Cell Death
19%
Gap Junction
18%
Cabozantinib
18%
Osteocyte
18%
Cancer Growth
16%
Xenograft
15%
Cancer
14%
Bone Morphogenetic Protein 4
14%
Clinical Trial
14%
Protein Tyrosine Kinase
13%
Bone Atrophy
12%
Somatomedin C
12%
Dasatinib
12%
Castration Resistant Prostate Cancer
10%
Bone Development
10%
Tumor Cell
10%
Metastasis Potential
9%
Tumor Progression
9%
Osteoclast
9%
Adrenal Metastasis
9%
Cell Cycle
9%
Antifolate
9%
Tenascin
9%
Focal Adhesion Kinase
9%
Insulin Receptor
9%
Janus Kinase 1
9%
DNA Damage Response
9%
Exosome
9%
Colorectal Carcinoma
9%
Aurora Kinase Inhibitor
9%
DNA Binding Protein
9%
Synapsin I
9%
PARP Inhibitor
9%
Poly ADP Ribose Polymerase
9%
Aurora A Kinase
9%
Helicase
9%
Growth Inhibition
9%
Steroid Hormone
9%
Statin
9%
Biochemistry, Genetics and Molecular Biology
Osteoblast
48%
Androgen Receptor
39%
Cancer Cell
35%
Blood Plasma
28%
Osteolysis
22%
Bone Morphogenetic Protein 4
22%
Programmed Cell Death
19%
Ossification
19%
Synapsin I
18%
Glucocorticoid Receptor
18%
Cabozantinib
18%
Reprogramming
18%
Osteocyte
18%
Long Noncoding RNA
18%
Mouse Model
15%
Tumor Progression
15%
Immune Checkpoints
14%
Transforming Growth Factor Beta Induced
12%
Mineralization
11%
Osteoclast
11%
Cell Migration
10%
Tenascin C
10%
Cell Survival
9%
Clinical Trial
9%
DNA-binding Protein
9%
Cell Adhesion
9%
Antifolate
9%
Chromosome Instability
9%
Janus Kinase 1
9%
Stromal Cell
9%
CHD1
9%
Fibroblast Growth Factor Receptor 1
9%
Precursor
9%
Statin
9%
Tyrosine
9%
Protein Kinase
9%
MST1
9%
Helicase
9%
Aurora Kinase
9%
Janus Kinase
9%
TPX2
9%
Bone Development
9%
Chromodomain
9%
Long Non-Coding RNA
9%
Single Nucleotide Polymorphism
9%
Non-Coding RNA
9%
Hydroxylation
9%
Cadherin
9%
DNA Damage Response
9%
Coculture
9%
Keyphrases
Prostate Cancer
46%
Prostate Cancer Cells
25%
Phosphorylation
24%
Prostate Cancer Metastasis
23%
Osteoblast
21%
Bone Metastasis
21%
Integrin
19%
Glucocorticoid Receptor
18%
Androgen Signaling
18%
Plasma-derived Extracellular Vesicles
18%
Tumor
14%
Apoptosis
13%
Endothelial Cells
13%
Metastatic Potential
12%
Androgen Receptor
12%
Prostate Cancer Progression
11%
Focal Adhesion Kinase
11%
Enzalutamide
11%
Knockdown
11%
Castration-resistant Prostate Cancer
10%
Reporter Mice
10%
Prostate Cancer Bone Metastasis
9%
LNCaP
9%
Insulin-like Growth factor-1
9%
Receptor Cells
9%
Gap Junction
9%
Tubulin
9%
Oxaliplatin
9%
Aurora Kinase A (AURKA)
9%
IGF1R Signaling
9%
Cadherin-11
9%
TBX5
9%
Tenascin-C
9%
Cell Division Cycle 6
9%
Renal Cell Carcinoma
9%
Stromal Reprogramming
9%
Mouse Bone
9%
Decreased Bone Density
9%
VEGFR-2 Inhibitors
9%
Serous Ovarian Carcinoma
9%
Ligand-independent Activation
9%
Radium-223
9%
Bone Development
9%
Statins
9%
Aurora Kinase Inhibitor
9%
Coactivator
9%
CKAP2
9%
Cabozantinib
9%
ATR-CHK1
9%
Antifolate Therapy
9%